Accelerating Opportunity

The U.S. Census Bureau projects that the population over the age of 65 will increase from 35 million in 1999 to approximately 70 million by the year 2030. We believe that this aging of the U.S. population, and similar trends in other developed countries, will contribute to increased demand for new and effective ophthalmic products.

InSite Vision's business strategy is focused on accelerating ophthalmic product opportunities that are consistent with our core competencies and allow us to address expanding needs in growing markets. We are addressing these opportunities in a variety of ways:

• Support and extend AzaSite^® in the U.S. and abroad: We are committed to working closely with our commercial partners to increase AzaSite sales in the U.S. and abroad, bringing this novel anti-infective to more patients worldwide.  AzaSite is currently approved in the United States and Canada, and was launched in the U.S. in August 2007 by Inspire Pharmaceuticals, our North American commercial partner.  We have also formed a number of strategic licensing and distribution agreements with partners to market AzaSite in select countries in Europe, Asia and South America upon regulatory approval in those regions.
• Launch new development partnerships: Our portfolio of ophthalmology products includes ISV-502 (AzaSite Plus™) and early-stage product opportunities based on our DuraSite drug delivery platform.  We plan to continue development of these existing assets, as needed, to support licensing opportunities that will maximize their value.  We are also seeking potential licensing partners for new applications of our DuraSite technology.
• Seek promising new late-stage products and technologies for in-licenisng or acquisition: Applying our expertise in ophthalmology and leveraging revenue from our commercial partnerships, we are actively working to identify, in-license or acquire promising new product candidates to fuel our R&D pipeline.  We are focused on ophthalmology drugs and devices that are in late-stage clinical evaluation or close to market.
• Executing on plan with operational discipline: Implementation of our strategy will be guided by milestone-driven decision making and the careful management of resources.  We will routinely evaluate expenses and seek means by which we can enhance operating efficiencies.